title: Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results.
abstract: BACKGROUND
  Chemotherapy is emerging in the management of advanced penile cancer.
  
  
  OBJECTIVE
  To evaluate the therapeutic activity of taxanes (T) in combination with cisplatin-fluorouracil (PF) for salvage of primarily unresectable or relapsed nodal metastases from squamous cell carcinoma (SCC) of the penis.
  
  
  METHODS
  Six consecutive patients were treated at Istituto Nazionale Tumori (INT), Milano, with neoadjuvant paclitaxel, cisplatin, and 5-fluorouracil (TPF) for unresectable (two cases) or recurrent nodal metastases (four cases) from SCC of the penis from 2004 to 2006. Informed consent was given by all patients.
  
  
  METHODS
  Four courses of neoadjuvant TPF were to be given before salvage surgery.
  
  
  METHODS
  Patients underwent computed tomography (CT) scans before starting chemotherapy, after two courses, and at the end of chemotherapy. Lymph node dissection was to be performed in responsive patients.
  
  
  CONCLUSIONS
  Two patients received more than four courses: Both had pathologically documented complete remission, and they are alive and disease free >2 yr after chemotherapy. The other four patients received only two courses. The first patient had subjective intolerance to TPF: He underwent early postchemotherapy radical lymph node dissection, which documented >90% tumour necrosis: He is alive and disease free 46 mo after starting chemotherapy. Of the other three patients, one was not responsive, changed therapy, and died within 4 mo. The other two had a clinical complete remission after the first two courses. Both refused to complete chemotherapy, and they relapsed after 10 and 4 mo. Limitations are the small number of patients and protocol violation in three cases.
  
  
  CONCLUSIONS
  TPF chemotherapy for unresectable or recurrent nodal metastases from SCC of the penis is promising, and the standard four courses of therapy are to be completed in responding patients. A larger series is necessary to confirm preliminary results.
authors.affiliation: Urologic Clinic 2nd, S. Giuseppe Hospital, Milan University, Milan, Italy. pizzocaro@iol.it
authors.forename: Giorgio
authors.initials: G
authors.lastname: Pizzocaro
authors.forename: Nicola
authors.initials: N
authors.lastname: Nicolai
authors.forename: Angelo
authors.initials: A
authors.lastname: Milani
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D010412:Penile Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D043823:Taxoids; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil